AUROPHARMA - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.6
| Stock Code | AUROPHARMA | Market Cap | 86,788 Cr. | Current Price | 1,494 ₹ | High / Low | 1,550 ₹ |
| Stock P/E | 35.7 | Book Value | 391 ₹ | Dividend Yield | 0.27 % | ROCE | 13.0 % |
| ROE | 11.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,421 ₹ | DMA 200 | 1,289 ₹ |
| Chg in FII Hold | 1.29 % | Chg in DII Hold | -1.84 % | PAT Qtr | 692 Cr. | PAT Prev Qtr | 595 Cr. |
| RSI | 59.9 | MACD | 1.68 | Volume | 26,28,140 | Avg Vol 1Wk | 18,15,118 |
| Low price | 1,016 ₹ | High price | 1,550 ₹ | PEG Ratio | 1.38 | Debt to equity | 0.19 |
| 52w Index | 89.4 % | Qtr Profit Var | 69.6 % | EPS | 41.6 ₹ | Industry PE | 32.5 |
AUROPHARMA shows decent potential for swing trading. The valuation is slightly above the industry average with a P/E of 35.7 vs 32.5, but fundamentals are stable. ROCE (13.0%) and ROE (11.2%) are moderate, while debt-to-equity (0.19) is manageable. Technical indicators are supportive: RSI at 59.9 suggests mild bullishness, and MACD at 1.68 indicates positive momentum. The stock is trading above both 50 DMA (1,421 ₹) and 200 DMA (1,289 ₹), showing strength. PAT growth (692 Cr vs 595 Cr) is encouraging, and the PEG ratio (1.38) suggests valuation is reasonable relative to growth. Volume is strong compared to average, reflecting active participation.
🔑 Optimal Entry Price: 1,450–1,470 ₹ (near 50 DMA support).
📤 Exit Strategy if Holding: Consider exiting near 1,540–1,550 ₹ resistance unless momentum continues strongly.
✅ Positive
- 📈 Strong quarterly PAT growth (692 Cr vs 595 Cr).
- 📊 Reasonable PEG ratio (1.38) supports valuation relative to growth.
- 📉 Manageable debt-to-equity ratio (0.19).
- 📈 RSI and MACD show bullish momentum.
- 📊 FII holdings increased (+1.29%), signaling foreign investor confidence.
⚠️ Limitation
- 📉 ROCE and ROE are moderate, not very high.
- 📊 P/E ratio (35.7) is slightly above industry average (32.5).
- 📉 DII holdings decreased (-1.84%), showing reduced domestic institutional interest.
📰 Company Negative News
- 📉 Decline in DII holdings may signal cautious domestic sentiment.
- ⚠️ Valuation slightly stretched compared to industry peers.
🌟 Company Positive News
- 📈 Strong quarterly profit growth (+69.6%).
- 📊 EPS at 41.6 ₹ indicates solid earnings base.
- 📉 FII confidence with increased stake.
- 📈 Stock trading above DMA levels shows strength.
🏭 Industry
- 📊 Industry P/E at 32.5, slightly lower than AUROPHARMA.
- 📈 Pharma sector benefits from defensive demand and global opportunities.
- ⚠️ Valuation gap may limit upside compared to peers.
📌 Conclusion
AUROPHARMA is a moderately strong swing trade candidate. Entry is best near 1,450–1,470 ₹ with cautious exit around 1,540–1,550 ₹. Fundamentals are stable, technicals show bullish momentum, and valuation is reasonable relative to growth. Suitable for traders looking for short-term gains with controlled risk.